AbCellera Biologics Inc. (NASDAQ: ABCL) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 2 articles on ABCL since Wednesday, June 17, 2026, most recently "AbCellera's ABCL635 Hits Phase 2 Primary Endpoints for Hot Flash Treatment With Single Dose" on Monday, August 10, 2026. Coverage to date spans Health Care, tracking ABCL's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
ABCL635 cut hot flash frequency by 83% vs 33% for placebo at week 4, with a single subcutaneous dose meeting both primary Phase 2 endpoints.
Jazz Pharmaceuticals is paying AbCellera $56M upfront, with up to $792M more per program, to co-develop next-gen cancer-fighting antibodies.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.